Immune Design is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is focused on oncology and have engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells, or CTLs, to fight cancer. Its immuno-oncology product candidates are being developed in two separate approaches: one that targets specific antigens and/or epitopes; and an alternative approach that leverages the endogenous antigens found in the tumor microenvironment via intratumoral immunization. The specific antigen approach uses selected antigens that are also present in the patient’s tumor so that the immune system will be educated to recognize the tumor antigen and kill tumor cells expressing the antigen.

Employee Rating

5.0More
TypePublic
HQSeattle, US
Founded2008
Size (employees)55 (est)+10%
Websiteimmunedesign.com
Immune Design was founded in 2008 and is headquartered in Seattle, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Immune Design Office Locations

Immune Design has offices in Seattle and South San Francisco
Seattle, (HQ)
310 1616 Eastlake Ave E
South San Francisco,
250 601 Gateway Blvd
Show all (2)
Report incorrect company information

Immune Design Financials and Metrics

Immune Design Revenue

Immune Design's revenue was reported to be $7.20 m in FY, 2017
USD

Revenue (Q3, 2018)

462.0k

Gross profit (Q3, 2018)

430.0k

Gross profit margin (Q3, 2018), %

93.1%

Net income (Q3, 2018)

(14.0m)

EBIT (Q3, 2018)

(14.6m)

Market capitalization (4-Dec-2018)

84.8m

Closing stock price (4-Dec-2018)

1.8

Cash (30-Sep-2018)

68.5m
Immune Design's current market capitalization is $84.8 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

9.5m13.3m7.2m

Cost of goods sold

774.0k481.0k84.0k

Gross profit

8.7m12.8m7.1m

Gross profit Margin, %

92%96%99%
Quarterly
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.1m3.5m1.8m4.7m1.9m1.1m8.2m5.5m729.0k516.0k503.0k755.0k462.0k

Cost of goods sold

18.0k31.0k44.0k298.0k22.0k253.0k72.0k37.0k18.0k16.0k7.0k140.0k32.0k

Gross profit

1.0m3.5m1.7m4.4m1.8m880.0k8.1m5.4m711.0k500.0k496.0k615.0k430.0k

Gross profit Margin, %

98%99%98%94%99%78%99%99%98%97%99%81%93%
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

112.9m45.2m72.5m

Accounts Receivable

972.0k517.0k647.0k

Inventories

13.0k607.0k684.0k

Current Assets

115.6m114.1m153.1m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(39.4m)(53.5m)(51.9m)

Depreciation and Amortization

243.0k304.0k351.0k

Inventories

12.0k(594.0k)(77.0k)

Accounts Payable

(3.8m)1.5m(2.2m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metricswdxefcqufszuzezftuxetqsqxt

Immune Design Operating Metrics

FY, 2016

Patents (Foreign)

19

Phase I Trials Products

1

Phase II Trials Products

3

Preclinical Phase Products

2
Show all operating metrics
Report incorrect company information

Immune Design News and Updates

Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab

SEATTLE and SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced long-term follow up results from a randomized Phase 2 clinical trial of 10 ug intratumor…

Immune Design to Present at Jefferies 2018 London Healthcare Conference

SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2018 London …

Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Conference call at 1:30 pm Pacific today

Immune Design to Report Third Quarter 2018 Financial Results and Provide Corporate Update

SEATTLE and SOUTH SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report third quarter 2018 financial results after the close of U.S. financial markets on Tuesday,…

Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305

SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced program updates for its G100 intratumoral TLR4 agonist and CMB305 cancer vaccine programs in developme…

Immune Design to Present at Upcoming September Investor Conferences

SEATTLE and SOUTH SAN FRANCISCO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that senior management will present at the following upcoming investor conferences:
Show more
Report incorrect company information

Immune Design Blogs

Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update Content Import Wed, 08/01/2018 - 16:03 Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update Aug 01, 2018 This release is a backfill from a News Wire …

Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update

Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update Content Import Wed, 07/25/2018 - 08:03 Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update Jul 25, 2018 This release is a backfill from a News Wir…

Immune Design Company Life and Culture

Report incorrect company information

Immune Design Frequently Asked Questions

  • When was Immune Design founded?

    Immune Design was founded in 2008.

  • How many employees does Immune Design have?

    Immune Design has 55 employees.

  • What is Immune Design revenue?

    Latest Immune Design annual revenue is $7.2 m.

  • What is Immune Design revenue per employee?

    Latest Immune Design revenue per employee is $130.8 k.

  • Who are Immune Design competitors?

    Competitors of Immune Design include Aptevo Therapeutics, Cleveland BioLabs and Heat Biologics.

  • Where is Immune Design headquarters?

    Immune Design headquarters is located at 310 1616 Eastlake Ave E, Seattle.

  • Where are Immune Design offices?

    Immune Design has offices in Seattle and South San Francisco.

  • How many offices does Immune Design have?

    Immune Design has 2 offices.